Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis.

Cancer chemotherapy and pharmacology - 1 Aug 2013

Zeng Zhiyu, Liu Yanqiong, Liu Zhiming, You Jianpeng, Chen Zhiping, Wang Jian, Peng Qiliu, Xie Li, Li Ruolin, Li Shan, Qin Xue

Abstract excerpt

PURPOSE: To evaluate whether breast cancer (BC) patients with CYP2D6 gene variation have different clinical tamoxifen (TAM) treatment outcomes to those with normal function of CYP2D6. METHODS: Systematic searches of the PubMed up to February 21, 2013, were retrieved. The study end points were disease-free survival (DFS) and overall survival (OS). Fixed or random-effects meta-analytical models were used to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Disease-Free Survival

Share to Proportional Hazards Models

Share to Publication Bias

Share to Survival Analysis

Share to Tamoxifen

Source

Identifiers

PMID: 23712329
DOI: 10.1007/s00280-013-2195-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis.PMID 23712329Read ↗

CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.Semantic proximity Read ↗

Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment.Semantic proximity Read ↗

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics.Semantic proximity Read ↗

The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.Semantic proximity Read ↗

Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer.Semantic proximity Read ↗

CYP2D6 genotyping and the clinical impact on outcomes in breast cancer tamoxifen-treated patients.Semantic proximity Read ↗

CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapySemantic proximity Read ↗

Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in Thailand.Semantic proximity Read ↗

CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.Semantic proximity Read ↗

Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen.Semantic proximity Read ↗

Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.Semantic proximity Read ↗

The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.